CommercialPrior AuthMedium impact
08.02.01d, Mirvetuximab soravtansine-gynx (Elahere®)
Independence Blue Cross·Oncology, OB-GYN·Pharmacy
Effective date
Jun 15, 2026
We identified it
Jun 19, 2026
Summary
The insurance company has updated the medical necessity criteria for Mirvetuximab soravtansine-gynx (Elahere®), a specialty oncology medication. This change affects prior authorization requirements and coverage criteria for this specific drug used in cancer treatment.
Action Required
Before June 15, 2026: Providers prescribing Mirvetuximab soravtansine-gynx (Elahere®) must review updated medical necessity criteria and ensure documentation meets new requirements. Billing team should update prior authorization protocols for this specialty oncology drug. Verify current criteria at medpolicy.ibx.com before submitting authorization requests.